Ioannis K. Zervantonakis

This study shows that chemotherapy-induced senescence-associated secretome promotes metastasis in ovarian cancer by reprogramming metabolism and increasing cell detachment.

This study shows that chronic inflammation and hormonal changes in older women create a tumor-permissive environment for ER+ breast cancer by increasing local estradiol and immune dysfunction.

This study identifies RHOV as a detachment-sensitive Rho GTPase critical for ovarian cancer peritoneal metastasis by enhancing anoikis resistance and cytoskeletal remodeling.

This paper introduces a 3D-printed microfluidic insert to pattern hydrogel arrays and generate gradients, enabling study of cell-cell and cell-ECM interactions in 3D microenvironments.

This study establishes patient-derived organoids (PDOs) for HNSCC drug response testing, integrating AI-driven histopathology and multi-omics analysis to create a scalable preclinical model.

This paper shows that stress signals from peripheral tissues can influence neuronal behavior in C. elegans by modulating lysosomal function and neurophysiology.

BESTDR quantifies drug response mechanisms using Bayesian modeling of cell state transitions, improving accuracy in dose-response analysis across cell lines.

The paper identifies S100A11 as a factor promoting macrophage recruitment in ER+ breast cancer through single-cell RNA-sequencing analysis and functional experiments.

This study identifies PAI1 and PLK1 as predictors of fibroblast-mediated resistance in HER2+ breast cancer and shows that targeting these proteins with lapatinib improves treatment efficacy.

This study uses a microwell platform to analyze CAR T cell infiltration and cytotoxicity in 3D breast cancer spheroids, identifying factors like spheroid size and seeding density that influence anti-tumor activity.

The paper compiles protein response data from cancer cell lines to drug perturbations, showing improved drug sensitivity prediction and building a protein-drug connectivity map with an accessible data portal.

The paper develops a temporal modeling framework to link protein changes to drug responses in melanoma cells, identifying effective therapies through experimental validation.